U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07354282) titled 'Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma' on Sept. 24, 2025.
Brief Summary: The SOGUG-TIVOREAL study is a retrospective observational study with medications.
This study is based on the retrospective collection of data from patients who have been treated with Tivozanib as first-line therapy between 03/01/2019 and 08/31/2024 for metastatic renal cell carcinoma (mRCC).
Study Start Date: May 13, 2025
Study Type: OBSERVATIONAL
Condition:
Renal Cell Cancer Metastatic
Recruitment Status: COMPLETED
Sponsor: Spanish Oncology Genito-Urinary Group
Disclaimer: Curated by HT ...